Dr. Nancy L. Kuntz

Pediatric Neurology | Neurology
225 E Chicago Ave # 51, 
Chicago, IL 
225 E Chicago Ave # 51, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nancy Kuntz is a Pediatric Neurologist and a Neurologist in Chicago, Illinois. Dr. Kuntz is rated as an Experienced provider by MediFind in the treatment of Satoyoshi Syndrome. Her top areas of expertise are Spinal Muscular Atrophy (SMA), Duchenne Muscular Dystrophy, Tubular Aggregate Myopathy, X-Linked Myotubular Myopathy, and Thymectomy.

Her clinical research consists of co-authoring 87 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Neurology
Neurology
Licenses
Neurology with Special Qualifications in Neurology in IL
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

225 E Chicago Ave # 51, Chicago, IL 60611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: November 18, 2025
Intervention Type: Drug
Study Drugs: SRP-4045 Exon 45-Skipping Treatment, SRP-4053 Exon 53-Skipping Treatment
Study Phase: Phase 3
An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
Enrollment Status: Completed
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drug: Nusinersen
Study Phase: Phase 2
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
Enrollment Status: Completed
Publish Date: July 08, 2025
Intervention Type: Genetic
Study Phase: Phase 3
Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
Enrollment Status: Completed
Publish Date: June 05, 2025
Intervention Type: Drug
Study Drug: Nusinersen
Study Phase: Phase 3
TAM4MTM: a Phase 1/2 Randomized, Placebo-Controlled, Double-Blinded, Single Crossover Study to Determine the Safety and Efficacy of Tamoxifen Therapy for Myotubular Myopathy (XLMTM)
TAM4MTM: a Phase 1/2 Randomized, Placebo-Controlled, Double-Blinded, Single Crossover Study to Determine the Safety and Efficacy of Tamoxifen Therapy for Myotubular Myopathy (XLMTM)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: ApoTamox
Study Phase: Phase 1/Phase 2
An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051
An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: SRP-5051
Study Phase: Phase 1/Phase 2
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Enrollment Status: Terminated
Publish Date: April 24, 2023
Intervention Type: Biological
Study Phase: Phase 1
A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study With Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study With Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Completed
Publish Date: March 09, 2023
Intervention Type: Drug, Other
Study Drugs: Vamorolone, Prednisone
Study Phase: Phase 2
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Enrollment Status: Completed
Publish Date: August 16, 2022
Intervention Type: Biological
Study Phase: Phase 3
Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen
Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen
Enrollment Status: Completed
Publish Date: August 12, 2022
Intervention Type: Drug
Study Phase: Phase 3
The RECENSUS Study: A Medical Chart Review of Patients With X-Linked Myotubular Myopathy (XLMTM)
The RECENSUS Study: A Medical Chart Review of Patients With X-Linked Myotubular Myopathy (XLMTM)
Enrollment Status: Completed
Publish Date: July 29, 2022
Intervention Type: Other
A Phase 1 Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Treatment
A Phase 1 Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Treatment
Enrollment Status: Completed
Publish Date: July 06, 2022
Intervention Type: Drug
Study Phase: Phase 1
A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-Term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-Term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Completed
Publish Date: May 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Completed
Publish Date: July 23, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Completed
Publish Date: January 02, 2019
Intervention Type: Drug
Study Phase: Phase 2
Phase 2 Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy
Phase 2 Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: December 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 16 Less Clinical Trials

87 Total Publications

A plain language summary of the SAPPHIRE clinical trial of apitegromab in children and young adults with spinal muscular atrophy.
A plain language summary of the SAPPHIRE clinical trial of apitegromab in children and young adults with spinal muscular atrophy.
Journal: Expert review of neurotherapeutics
Published: November 13, 2025
Similar Doctors
Syed M. Munzir
Advanced in Satoyoshi Syndrome
Dr. Syed M. Munzir
Neurology
Advanced in Satoyoshi Syndrome
Dr. Syed M. Munzir
Neurology

Advanced Neurology And Sleep Clinic, LLC

40 N Airlite St, 
Elgin, IL 
 (37.6 miles away)
847-628-9977
Languages Spoken:
English, Urdu
See accepted insurances

Syed Munzir is a Neurologist in Elgin, Illinois. Dr. Munzir is rated as an Advanced provider by MediFind in the treatment of Satoyoshi Syndrome. His top areas of expertise are Memory Loss, Obstructive Sleep Apnea, Seizures, and Excessive Daytime Sleepiness.

Experienced in Satoyoshi Syndrome
Dr. Octavia Kincaid
Neurology
Experienced in Satoyoshi Syndrome
Dr. Octavia Kincaid
Neurology

Northshore Integrated Pain Center-Evanston

1000 Central St Ste 880, 
Evanston, IL 
 (12.0 miles away)
847-570-2570
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Octavia Kincaid is a Neurologist in Evanston, Illinois. Dr. Kincaid is rated as a Distinguished provider by MediFind in the treatment of Satoyoshi Syndrome. Her top areas of expertise are Familial Dysautonomia, Myasthenia Gravis, Peripheral Neuropathy, and Spinal Muscular Atrophy (SMA).

Experienced in Satoyoshi Syndrome
Dr. Surendra M. Gulati
Neurology
Experienced in Satoyoshi Syndrome
Dr. Surendra M. Gulati
Neurology

Prime Healthcare Illinois Medical Group LLC

201 N Hammes Ave, 
Joliet, IL 
 (36.7 miles away)
224-273-6350
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Surendra Gulati is a Neurologist in Joliet, Illinois. Dr. Gulati is rated as an Advanced provider by MediFind in the treatment of Satoyoshi Syndrome. His top areas of expertise are Parkinson's Disease, Headache, Peripheral Neuropathy, and West Syndrome. Dr. Gulati is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kuntz's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 17 Advanced Conditions
View All 188 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile